Mogelijk gemaakt door 
Translate
Translate
THOUSAND OAKS, CA /ACCESSWIRE/ January 22, 2020. CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc (OTC PINK: CBDG) today announced that the Company incorporated a subsidiary (Medical Mushrooms, Ltd.) for the purpose of conducting clinical trials involving the combination of genetic testing and micro-dosing of psilocybin.
Due to the State of Colorado having taken a lead in legalization of psilocybin for medical purposes, we chose Colorado as the best state for conducting upcoming clinical trials.
“We intend to become the first publicly owned company to enter this important field of research and development. We are well positioned to begin clinical trials involving psilocybin since we have already cleared a path for cannabis related clinical trials. The purpose of this division is to engage in advanced research of the growing niche of pharmaceutical grade medicinal mushrooms including psychedelics. The company has registered the following domain names:
http://www.magicpharmaceuticals.com
A psilocybin mushroom is one of a polyphyletic group of fungi that contain any of various psychedelic compounds, including psilocybin, psilocin, and baeocystin.
Common, colloquial terms for psilocybin mushrooms include psychedelic mushrooms, booms, magic mushrooms, shrooms, and mush. Biological genera containing psilocybin mushrooms include Copelandia, Gymnopilus, Inocybe, Mycena, Panaeolus, Pholiotina, Pluteus, and Psilocybe. Psilocybin mushrooms may have been used in ancient religious rites and ceremonies. They may be depicted in Stone Age rock art in Africa and Europe, but are most famously represented in the Pre-Columbian sculptures and glyphs seen throughout Central and South America.
Psychedelics Help Reduce Opioid Addiction, According to Recent Study by Jag Davies published on Drugpolicy.org
“The criminalization of people who use psychedelics is rooted in myths that are the vestiges of colonialism and the drug war – and, one by one, those myths are crumbling down.
“We’ve learned in recent years that people who use psychedelics are significantly *less* likely to end up developing mental health problems, perpetrating domestic violence, or suffering from psychological distress and suicidal thinking.
“Meanwhile, recent research has shown that psychedelic-assisted psychotherapy can be an effective treatment for people struggling with difficult-to-treat conditions such as substance use disorders. Not much has been known, though, about the connection between psychedelic use and substance misuse in the general population.
“Now, a new study published in the Journal of Psychopharmacology has found that experiences with psychedelics like LSD and psilocybin mushrooms are associated with decreased risk of opioid abuse and dependence among respondents with a history of illegal opioid use. Psychedelic use is associated with 27% reduced risk of past-year opioid dependence and 40% reduced risk of past-year opioid abuse. Other than marijuana use, which was associated with 55% reduced risk of past-year opioid abuse, no other illegal drug was associated with reduced risk of past-year opioid dependence or abuse.
“The study is based on six years of data from the federal government’s National Survey on Drug Use and Health (NSDUH), which surveys 70,000 people each year. While the findings are far from causal, the authors conclude that the associations between psychedelic use and opioid misuse are “pervasive and significant” and “suggest that psychedelics are associated with positive psychological characteristics and are consistent with prior reports suggesting efficacy in treatment of substance use disorders.”
“Although more research is needed to determine exactly why there’s such a strong correlation between psychedelic use and decreased risk of opioid misuse, this study does appear to validate the experiences of many people who have found substances like ibogaine, marijuana or kratom to be life-changing tools that have helped them lead happier, more fulfilling lives. For many, these substances have helped them cut back or quit their use of opioids or other substances with which they’ve had a problematic relationship. Safe access to these substances – along with 911 Good Samaritan laws, naloxone access programs, supervised injection facilities, various forms of maintenance therapy, and, of course, ending the criminalization of drug use – should be part of the discussion when it comes to dealing with addiction and skyrocketing rates of overdose deaths.
“While psychedelic-assisted therapy could be approved by the FDA in this decade, that would do nothing to change the criminal penalties faced by millions of people who use psychedelics outside of government-sanctioned, medically-supervised settings. That’s why it’s incumbent upon people who care about psychedelics to advocate for reducing the criminalization of people who use them outside of medical contexts, while also advocating for psychedelic-assisted therapy research.
“Given the widespread scientific consensus that drug use and addiction are best treated as health issues, there’s no good reason for people who use psychedelics to be treated as criminals – especially considering how much we already know about prohibition’s discriminatory impact on people of color and other marginalized groups.
“This study also forces us to reflect on why abstinence-only policies can be so harmful and counterproductive. Contrary to conventional wisdom, federal government data has consistently shown that the vast majority of people who use opioids, including heroin, don’t end up developing an addiction. So, our focus should be not just on preventing people from using opioids – after all, they can be essential medical tools – but also ensuring, above all else, that people who use them don’t go on to struggle with addiction.
“A truly health-centred approach to drug addiction assesses improvement by many measures, not simply by someone’s drug use level, but also by their overall health, their social relationships, and their general well-being. Determining success by boiling it down to the single measure of abstinence to an arbitrary group of certain drugs isn’t realistic or effective.
“Addiction is a complex phenomenon, but I think it’s safe to say that it can only be genuinely resolved when people find meaning in their lives. This study is yet another indication that the meaning people seem to find from psychedelics has considerable implications for our prevailing healthcare and criminal justice paradigms.”
About CBDual Biotechnology Corp.
THC Farmaceuticals, Inc.: (OTC: CBDG) through its subsidiary, CBDual Biotechnology Corp., is a pharmaceutical start-up company focuses on developing products based on cannabidiol (CBD) and/or Tetrahydrocannabinol (THC). The company's facility is located in Southern California where we provide easy access for patients to participate in clinical trials of new medical cannabis medications, therapies, and products. CBDual Biotechnology Corp is a privately held, US Based Biotechnology company with propriety technology for enhanced oral delivery of bioactive cannabinoids. This technology promotes overall oral health due to higher effectiveness of the delivery methodology. The company was founded in 2016 and is headquartered in California, with its R&D in the US and Israel. Recently the Company had formed a new division - Medical Mushrooms, Ltd to enter new developments in growing trend to decriminalize Psilocybin and will engage in clinical trials
For additional information visit the company's website: http://cbdual.com/and
http://cbdg.com/Follow us on Twitter @THCFarma and @CBDualBiotech
Forward-Looking Statements:
This press release contains "forward-looking statements." Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by our parent company in its reports filed with the Securities and Exchange Commission and the OTCMarkets, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
